Uptake studies with chondrotropic 99mTc-chondroitin sulfate in articular cartilage. Implications for imaging osteoarthritis in the knee

Sobal, Grazyna; Dorotka, Ronald; Menzel, J; Sinzinger, H.

doi:10.1016/j.nucmedbio.2013.07.007

Cited by 13 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As reviewed in recent works404142, the mechanism of action of CS differs in several aspects from that of GlcN. In vivo and in vitro experiments have demonstrated that CS reaches the joint, and distributes into the cartilage and subchondral layers4344. However, being a large molecule, CS does not penetrate into the cells45, and so elicits its anti-inflammatory effect by engaging chondrocytes membrane receptors, e.g.…”

Section: Discussionmentioning

confidence: 99%

A pharmacoproteomic study confirms the synergistic effect of chondroitin sulfate and glucosamine

Calamia

Mateos

Fernández-Puente

et al. 2014

Sci Rep

View full text Add to dashboard Cite

Osteoarthritis (OA) is the most common age-related rheumatic disease. Chondrocytes play a primary role in mediating cartilage destruction and extracellular matrix (ECM) breakdown, which are main features of the OA joint. Quantitative proteomics technologies are demonstrating a very interesting power for studying the molecular effects of some drugs currently used to treat OA patients, such as chondroitin sulfate (CS) and glucosamine (GlcN). In this work, we employed the iTRAQ (isobaric tags for relative and absolute quantitation) technique to assess the effect of CS and GlcN, both alone and in combination, in modifying cartilage ECM metabolism by the analysis of OA chondrocytes secretome. 186 different proteins secreted by the treated OA chondrocytes were identified. 36 of them presented statistically significant differences (p ≤ 0.05) between untreated and treated samples: 32 were increased and 4 decreased. The synergistic chondroprotective effect of CS and GlcN, firstly reported by our group at the intracellular level, is now demonstrated also at the extracellular level.

show abstract

Section: Discussionmentioning

confidence: 99%

A pharmacoproteomic study confirms the synergistic effect of chondroitin sulfate and glucosamine

Calamia

Mateos

Fernández-Puente

et al. 2014

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In its anti-inflammatory actions it reduces pro-inflammatory factors, proteases and improves the anabolic/catabolic balance of the extracellular cartilage matrix (ECM) [85], also reduces the cartilage volume loss [86], decreases the synovial histopathological lesions [87], pain reduction and declination of joint space [88], delay many inflammation-induced catabolic processes in the cartilage [89], reduces the matrix metalloproteases (MMP), key proteases that are specifically related to articular tissues, including MMP-3, MMP-9, MMP-13, and MT1-MMP or MMP-14 [90] CS can impact processes associated with cartilage degeneration; induces the production of proteoglycans by the expression vector for the glycosyltransferase β-1,3-glucuronosyltransferase-I (GlcAT-I) promotion [91], inhibiting elastase and cathepsin G activity [92], reducing gene expression for a range of proteolytic enzymes [93]. The uptake studies indicate that (99 m)Tc-CS accumulates in articular cartilage and prove its chondrotropic effects [94]. CS protects against hydrogen peroxide formation and superoxide anions [95].…”

Section: Cs's Structure-modifying Role In Oamentioning

confidence: 99%

Chondroitin sulphate: a focus on osteoarthritis

et al. 2016

View full text Add to dashboard Cite

Chondroitin sulfate (CS) being a natural glycosaminoglycan is found in the cartilage and extracellular matrix. It shows clinical benefits in symptomatic osteoarthritis (OA) of the finger, knee, hip joints, low back, facial joints and other diseases due to its anti-inflammatory activity. It also helps in OA by providing resistance to compression, maintaining the structural integrity, homeostasis, slows breakdown and reduces pain in sore muscles. It is most often used in combination with glucosamine to treat OA. CS is a key role player in the regulation of cell development, cell adhesion, proliferation, and differentiation. Its commercial applications have been continuously explored in the engineering of biological tissues and its combination with other biopolymers to formulate scaffolds which promote and accelerate the regeneration of damaged structure. It is approved in the USA as a dietary supplement for OA, while it is used as a symptomatic slow-acting drug (SYSADOA) in Europe and some other countries. Any significant side effects or overdoses of CS have not been reported in clinical trials suggesting its long-term safety. This review highlights the potential of CS, either alone or in combination with other drugs, to attract the scientists engaged in OA treatment and management across the world.

show abstract

“…The available data from fundamental and clinical studies indicate significant differences in the efficacy and safety of various CS-based medications [30][31][32][33][34][35][36][37][38]. The pharmacological quality of CS is very important, since taking large doses of insufficiently purified CS can contribute to the development of adverse effects (increased transaminase levels, acute liver damage as in autoimmune hepatitis [39], a change in the level of pro-inflammatory factors [30], etc.…”

Section: Cs-based Commercial Therapiesmentioning

confidence: 99%

Molecular Effects of Chondroitin Sulfate in Osteoarthritis and Herniated Discs

Am¹,

Gromova²,

Torshin³

et al. 2018

JRAD

View full text Add to dashboard Cite

Background: Chondroitin sulfate (CS) is a glycosaminglycan constructed of repeating disaccharide units with the presence of an amino sugar and different sulfated positions. This compound is present in the extracellular matrix especially in the cartilage, skin, blood vessels, ligaments and tendons. CS aside of being a building material for the cartilage it also has anti-inflammatory and antioxidant effects. For these reasons CS is currently being therapeutically used for the treatment of osteoarthritis (OA) in many countries under the commercial name Chondroguard®. Aims: This review critically analyzes the therapeutic properties of CS in the vertebral unit by assessing relevant in vitro and in vivo data published during the last decades in the specialized literature. The molecular-physiological mechanisms of action of CS in intervertebral disc extrusions and protrusions, in inflammation and neuroprotection are discussed. Conclusions: The clinical data obtained during years of treatment with CS and the utility of this molecule to protect the functional spinal unit are also considered to highlight their potential to treat OA worldwide.

show abstract

Uptake studies with chondrotropic 99mTc-chondroitin sulfate in articular cartilage. Implications for imaging osteoarthritis in the knee

Cited by 13 publications

References 21 publications

A pharmacoproteomic study confirms the synergistic effect of chondroitin sulfate and glucosamine

A pharmacoproteomic study confirms the synergistic effect of chondroitin sulfate and glucosamine

Chondroitin sulphate: a focus on osteoarthritis

Molecular Effects of Chondroitin Sulfate in Osteoarthritis and Herniated Discs

Contact Info

Product

Resources

About